Semler Scientific, Inc. Logo

Semler Scientific, Inc.

SMLR

(2.8)
Stock Price

61,78 USD

53.01% ROA

20.31% ROE

11.25x PER

Market Cap.

179.142.470,00 USD

0.15% DER

0% Yield

27% NPM

Semler Scientific, Inc. Stock Analysis

Semler Scientific, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Semler Scientific, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (30.26%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 DER

The stock has a minimal amount of debt (13%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

5 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

6 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (164) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 PBV

The stock's high Price-to-Book Value (P/BV) ratio (4.02x) suggests it's overvalued, potentially making it an expensive investment.

8 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

9 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

10 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

11 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

Semler Scientific, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Semler Scientific, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Semler Scientific, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Semler Scientific, Inc. Revenue
Year Revenue Growth
2011 316.000
2012 1.199.000 73.64%
2013 2.274.000 47.27%
2014 3.635.000 37.44%
2015 7.001.000 48.08%
2016 7.434.000 5.82%
2017 12.452.000 40.3%
2018 21.491.000 42.06%
2019 32.767.000 34.41%
2020 38.603.000 15.12%
2021 53.027.000 27.2%
2022 56.686.000 6.45%
2023 65.264.000 13.14%
2023 68.184.000 4.28%
2024 57.860.000 -17.84%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Semler Scientific, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2011 246.000
2012 277.000 11.19%
2013 356.000 22.19%
2014 1.113.000 68.01%
2015 1.436.000 22.49%
2016 866.000 -65.82%
2017 1.831.000 52.7%
2018 2.085.000 12.18%
2019 2.479.000 15.89%
2020 2.938.000 15.62%
2021 3.780.000 22.28%
2022 4.809.000 21.4%
2023 4.696.000 -2.41%
2023 5.773.000 18.66%
2024 5.760.000 -0.23%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Semler Scientific, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 1.057.000
2012 1.255.000 15.78%
2013 1.317.000 4.71%
2014 2.448.000 46.2%
2015 4.871.000 49.74%
2016 3.027.000 -60.92%
2017 3.843.000 21.23%
2018 4.159.000 7.6%
2019 6.954.000 40.19%
2020 6.406.000 -8.55%
2021 9.235.000 30.63%
2022 12.737.000 27.49%
2023 14.840.000 14.17%
2023 14.290.000 -3.85%
2024 11.856.000 -20.53%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Semler Scientific, Inc. EBITDA
Year EBITDA Growth
2011 -1.785.000
2012 -2.548.000 29.95%
2013 -1.996.000 -27.66%
2014 -4.340.000 54.01%
2015 -8.419.000 48.45%
2016 -2.159.000 -289.95%
2017 -867.000 -149.02%
2018 5.338.000 116.24%
2019 10.701.000 50.12%
2020 15.961.000 32.96%
2021 19.445.000 17.92%
2022 17.792.000 -9.29%
2023 25.196.000 29.39%
2023 22.256.000 -13.21%
2024 22.180.000 -0.34%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Semler Scientific, Inc. Gross Profit
Year Gross Profit Growth
2011 171.000
2012 835.000 79.52%
2013 1.805.000 53.74%
2014 2.943.000 38.67%
2015 4.154.000 29.15%
2016 5.561.000 25.3%
2017 9.899.000 43.82%
2018 18.788.000 47.31%
2019 29.106.000 35.45%
2020 35.247.000 17.42%
2021 46.905.000 24.85%
2022 52.434.000 10.54%
2023 60.820.000 13.79%
2023 61.200.000 0.62%
2024 52.840.000 -15.82%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Semler Scientific, Inc. Net Profit
Year Net Profit Growth
2011 -1.876.000
2012 -2.741.000 31.56%
2013 -2.233.000 -22.75%
2014 -4.515.000 50.54%
2015 -8.501.000 46.89%
2016 -2.554.000 -232.85%
2017 -1.510.000 -69.14%
2018 5.014.000 130.12%
2019 15.084.000 66.76%
2020 14.007.000 -7.69%
2021 17.222.000 18.67%
2022 14.325.000 -20.22%
2023 22.056.000 35.05%
2023 20.583.000 -7.16%
2024 44.000 -46679.55%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Semler Scientific, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 -1
2012 -1 0%
2013 0 0%
2014 -1 100%
2015 -2 0%
2016 -1 0%
2017 0 0%
2018 1 0%
2019 2 100%
2020 2 0%
2021 3 0%
2022 2 0%
2023 3 33.33%
2023 3 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Semler Scientific, Inc. Free Cashflow
Year Free Cashflow Growth
2011 -1.462.000
2012 -2.011.000 27.3%
2013 -1.633.000 -23.15%
2014 -4.263.000 61.69%
2015 -5.239.000 18.63%
2016 -2.618.000 -100.11%
2017 -350.000 -648%
2018 3.853.000 109.08%
2019 11.030.000 65.07%
2020 14.356.000 23.17%
2021 15.231.000 5.74%
2022 15.303.000 0.47%
2023 4.682.000 -226.85%
2023 16.992.000 72.45%
2024 -55.033.000 130.88%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Semler Scientific, Inc. Operating Cashflow
Year Operating Cashflow Growth
2011 -1.275.000
2012 -1.821.000 29.98%
2013 -1.192.000 -52.77%
2014 -3.822.000 68.81%
2015 -4.135.000 7.57%
2016 -1.804.000 -129.21%
2017 621.000 390.5%
2018 4.697.000 86.78%
2019 12.728.000 63.1%
2020 15.417.000 17.44%
2021 16.056.000 3.98%
2022 17.463.000 8.06%
2023 4.831.000 -261.48%
2023 17.820.000 72.89%
2024 4.934.000 -261.17%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Semler Scientific, Inc. Capital Expenditure
Year Capital Expenditure Growth
2011 187.000
2012 190.000 1.58%
2013 441.000 56.92%
2014 441.000 0%
2015 1.104.000 60.05%
2016 814.000 -35.63%
2017 971.000 16.17%
2018 844.000 -15.05%
2019 1.698.000 50.29%
2020 1.061.000 -60.04%
2021 825.000 -28.61%
2022 2.160.000 61.81%
2023 149.000 -1349.66%
2023 828.000 82%
2024 59.967.000 98.62%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Semler Scientific, Inc. Equity
Year Equity Growth
2011 -469.000
2012 -3.575.000 86.88%
2013 -295.000 -1111.86%
2014 3.436.000 108.59%
2015 -1.072.000 420.52%
2016 -2.919.000 63.28%
2017 -2.583.000 -13.01%
2018 4.196.000 161.56%
2019 13.073.000 67.9%
2020 29.793.000 56.12%
2021 45.547.000 34.59%
2022 55.676.000 18.19%
2023 71.795.000 22.45%
2023 70.773.000 -1.44%
2024 78.398.000 9.73%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Semler Scientific, Inc. Assets
Year Assets Growth
2011 674.000
2012 1.476.000 54.34%
2013 1.724.000 14.39%
2014 7.500.000 77.01%
2015 3.079.000 -143.59%
2016 3.072.000 -0.23%
2017 4.238.000 27.51%
2018 7.719.000 45.1%
2019 18.287.000 57.79%
2020 34.639.000 47.21%
2021 50.672.000 31.64%
2022 62.693.000 19.17%
2023 78.065.000 19.69%
2023 79.443.000 1.73%
2024 84.786.000 6.3%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Semler Scientific, Inc. Liabilities
Year Liabilities Growth
2011 1.143.000
2012 5.051.000 77.37%
2013 2.019.000 -150.17%
2014 4.064.000 50.32%
2015 4.151.000 2.1%
2016 5.991.000 30.71%
2017 6.821.000 12.17%
2018 3.523.000 -93.61%
2019 5.214.000 32.43%
2020 4.846.000 -7.59%
2021 5.125.000 5.44%
2022 7.017.000 26.96%
2023 6.270.000 -11.91%
2023 8.670.000 27.68%
2024 6.388.000 -35.72%

Semler Scientific, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
8.89
Net Income per Share
2.28
Price to Earning Ratio
11.25x
Price To Sales Ratio
2.9x
POCF Ratio
10.9
PFCF Ratio
-4.11
Price to Book Ratio
2.27
EV to Sales
2.78
EV Over EBITDA
7.99
EV to Operating CashFlow
10.53
EV to FreeCashFlow
-3.94
Earnings Yield
0.09
FreeCashFlow Yield
-0.24
Market Cap
0,18 Bil.
Enterprise Value
0,17 Bil.
Graham Number
24.05
Graham NetNet
1.88

Income Statement Metrics

Net Income per Share
2.28
Income Quality
1.03
ROE
0.21
Return On Assets
0.17
Return On Capital Employed
0.23
Net Income per EBT
0.88
EBT Per Ebit
0.91
Ebit per Revenue
0.34
Effective Tax Rate
0.12

Margins

Sales, General, & Administrative to Revenue
0.21
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.88
Operating Profit Margin
0.34
Pretax Profit Margin
0.31
Net Profit Margin
0.27

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
2.35
Free CashFlow per Share
-6.28
Capex to Operating CashFlow
3.67
Capex to Revenue
0.97
Capex to Depreciation
90
Return on Invested Capital
0.23
Return on Tangible Assets
0.53
Days Sales Outstanding
44.95
Days Payables Outstanding
11.84
Days of Inventory on Hand
20.08
Receivables Turnover
8.12
Payables Turnover
30.82
Inventory Turnover
18.17
Capex per Share
8.63

Balance Sheet

Cash per Share
1,95
Book Value per Share
11,29
Tangible Book Value per Share
3.38
Shareholders Equity per Share
11.29
Interest Debt per Share
0.07
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-0.34
Current Ratio
3.72
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,02 Bil.
Invested Capital
74767000
Working Capital
0,02 Bil.
Intangibles to Total Assets
0.65
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
396500
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Semler Scientific, Inc. Dividends
Year Dividends Growth

Semler Scientific, Inc. Profile

About Semler Scientific, Inc.

Semler Scientific, Inc. provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.

CEO
Dr. Douglas Murphy-Chutorian
Employee
92
Address
2340-2348 Walsh Avenue
Santa Clara, 95051

Semler Scientific, Inc. Executives & BODs

Semler Scientific, Inc. Executives & BODs
# Name Age
1 Ms. Renae Cormier
Chief Financial Officer, Principal Accounting Officer, Head of Corporation Communications & Bus. Strategy and Secretary
70
2 Ms. Jennifer Oliva Herrington
Chief Operating Officer
70
3 Mr. Shane Reid
Chief Technology Officer
70
4 Dr. Douglas Murphy-Chutorian M.D.
Chief Executive Officer, President & Director
70
5 Ms. Cindy Guinasso
Senior Vice President of Business Development
70
6 Dr. Herbert J. Semler
Founder & Chairman Emeritus
70

Semler Scientific, Inc. Competitors

CVRx, Inc. Logo
CVRx, Inc.

CVRX

(1.0)
Surmodics, Inc. Logo
Surmodics, Inc.

SRDX

(0.8)
Pulmonx Corporation Logo
Pulmonx Corporation

LUNG

(1.2)
Heska Corporation Logo
Heska Corporation

HSKA

(1.0)
TELA Bio, Inc. Logo
TELA Bio, Inc.

TELA

(1.2)
NeuroPace, Inc. Logo
NeuroPace, Inc.

NPCE

(0.5)
ProSomnus, Inc. Logo
ProSomnus, Inc.

OSA

(2.2)
LivaNova PLC Logo
LivaNova PLC

LIVN

(2.2)
Electromed, Inc. Logo
Electromed, Inc.

ELMD

(2.0)
Artivion, Inc. Logo
Artivion, Inc.

AORT

(0.5)
Inogen, Inc. Logo
Inogen, Inc.

INGN

(1.2)